The “Non-viral” Approach for siRNA delivery in cancer treatment: A special focus on micelles and liposomes

DNA and RNA Nanobiotechnologies in Medicine: Diagnosis and Treatment of Diseases

Volumn , Issue , 2013, Pages 241-261

  Navarro, Gemma ^a   Essex, Sean ^a   Torchilin, Vladimir P ^a  

^a NORTHEASTERN UNIVERSITY   (United States)

Author keywords

Cancer; Cationic polymers; Liposomes; Micelles; RNAi; siRNA delivery

Indexed keywords

DISEASES; LIPOSOMES; MICELLES; ONCOLOGY; RNA;

CANCER; CANCER THERAPY; CATIONIC POLYMERS; INHERENT INSTABILITY; NON-VIRAL CARRIERS; RNAI; SIRNA DELIVERY; SMALL INTERFERING RNA (SIRNA);

GENE THERAPY;

EID: 85007211523     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1007/978-3-642-36853-0_10     Document Type: Chapter

References (107)

1. Akinc A, Zumbuehl A, Goldberg M et al (2008) A combinatorial library of lipid-like materials for delivery of RNAi therapeutics. Nat Biotechnol 26: 561-569
2. Akinc A, Goldberg M, Qin J et al (2009) Development of lipidoid-siRNA formulations for systemic delivery to the liver. Mol Ther 17: 872-879
3. Akinc A, Querbes W, De S et al (2010) Targeted delivery of RNAi therapeutics with endogenous and exogenous ligand-based mechanisms. Mol Ther 18: 1357-1364
4. Aleku M, Schulz P, Keil O et al (2008) Atu027, a liposomal small interfering RNA formulation targeting protein kinase N3, inhibits cancer progression. Cancer Res 68: 9788-9798
5. Alshamsan A, Haddadi A, Incani V et al (2009) Formulation and delivery of siRNA by oleic acid and stearic acid modified polyethylenimine. Mol Pharm 6: 121-133
6. Alshamsan A, Hamdy S, Samuel J et al (2010) The induction of tumor apoptosis in B16 melanoma following STAT3 siRNA delivery with a lipid-substituted polyethylenimine. Biomaterials 31: 1420-1428
7. Altieri DC (2008) Survivin, cancer networks and pathway-directed drug discovery. Nat Rev Cancer 8: 61-70
8. Baguley BC (2010) Multidrug resistance in cancer. In: Zhou J (ed) Multi-drug resistance in cancer, vol 596. Humana Press, Totowa, NJ, pp 1-14
9. Ballarin-Gonzalez B, Howard KA (2012) Polyplex-based delivery of RNAi therapeutics: adverse effects and solutions. Adv Drug Deliv Rev 64: 1717-1729
10. Benoit DSW, Henry SM, Shubin AD et al (2010) pH-responsive polymeric sirna carriers sensitize multidrug resistant ovarian cancer cells to doxorubicin via knockdown of polo-like kinase 1. Mol Pharm 7: 442-455
11. Beyerle A, Braun A, Merkel O et al (2011) Comparative in vivo study of poly (ethylene imine)/ siRNA complexes for pulmonary delivery in mice. J Control Release 151: 51-56
12. Bonnet ME, Erbacher P, Bolcato-Bellemin AL (2008) Systemic delivery of DNA or siRNA mediated by linear polyethylenimine (L-PEI) does not induce an inflammatory response. Pharm Res 25: 2972-2982
13. Boussif O, Lezoualc’h F, Zanta MA et al (1995) A versatile vector for gene and oligonucleotide transfer into cells in culture and in vivo: polyethylenimine. Proc Natl Acad Sci USA 92: 7297-7301
14. Brigger I, Dubernet C, Couvreur P (2002) Nanoparticles in cancer therapy and diagnosis. Adv Drug Deliv Rev 54: 631-651
15. Canine BF, Wang Y, Ouyang W et al (2011) Development of targeted recombinant polymers that can deliver siRNA to the cytoplasm and plasmid DNA to the cell nucleus. J Control Release 151: 95-101
16. Cao N, Cheng D, Zou S et al (2011) The synergistic effect of hierarchical assemblies of siRNA and chemotherapeutic drugs co-delivered into hepatic cancer cells. Biomaterials 32: 2222-2232
17. Chae SS, Paik JH, Furneaux H et al (2004) Requirement for sphingosine 1-phosphate receptor-1 in tumor angiogenesis demonstrated by in vivo RNA interference. J Clin Invest 114: 1082-1089
18. Chakravarti A, Noll E, Black PM et al (2002) Quantitatively determined survivin expression levels are of prognostic value in human gliomas. J Clin Oncol 20: 1063-1068
19. Chen H, Hao J, Wang L et al (2009) Coexpression of invasive markers (uPA, CD44) and multiple drug-resistance proteins (MDR1, MRP2) is correlated with epithelial ovarian cancer progression. Br J Cancer 101: 432-440
20. Choi SW, Lee SH, Mok H et al (2010) Multifunctional siRNA delivery system: polyelectrolyte complex micelles of six-arm PEG conjugate of siRNA and cell penetrating peptide with crosslinked fusogenic peptide. Biotechnol Prog 26: 57-63
21. Convertine A, Diab C, Prieve M, et al (2010) pH-responsive polymeric micelle carriers for siRNA drugs. Biomacromolecules 11: 2904-2911
22. Couto LB, High KA (2010) Viral vector-mediated RNA interference. Curr Opin Pharmacol 10: 534-542
23. Daniels TR, Delgado T, Helguera G et al (2006) The transferrin receptor part II: targeted delivery of therapeutic agents into cancer cells. Clin Immunol 121: 159-176
24. Davidson BL, McCray PB Jr (2011) Current prospects for RNA interference-based therapies. Nat Rev Genet 12: 329-340
25. Davis ME (2009) The first targeted delivery of siRNA in humans via a self-assembling, cyclodextrin polymer-based nanoparticle: from concept to clinic. Mol Pharm 6: 659-668
26. De Paula D, Bentley MV, Mahato RI (2007) Hydrophobization and bioconjugation for enhanced siRNA delivery and targeting. RNA 13: 431-456
27. Elbashir SM, Harborth J, Lendeckel W et al (2001) Duplexes of 21-nucleotide RNAs mediate RNA interference in cultured mammalian cells. Nature 411: 494-498
28. Elsabahy M, Wazen N, BayóPuxan N et al (2009) Delivery of nucleic acids through the controlled disassembly of multifunctional nanocomplexes. Adv Funct Mater 19: 3862-3867
29. Fire A, Xu S, Montgomery MK et al (1998) Potent and specific genetic interference by doublestranded RNA in Caenorhabditis elegans. Nature 391: 806-811
30. Gao Y, Liu XL, Li XR (2011) Research progress on siRNA delivery with nonviral carriers. Int J Nanomedicine 6: 1017
31. Gewirtz AM (2007) On future’s doorstep: RNA interference and the pharmacopeia of tomorrow. J Clin Invest 117: 3612
32. Gomes-da-Silva LC, Fonseca NA, Moura V et al (2012) Lipid-based nanoparticles for siRNA delivery in cancer therapy: paradigms and challenges. Acc Chem Res 45: 1163-1171
33. Grabowski P, Kuhnel T, Muhr-Wilkenshoff F et al (2003) Prognostic value of nuclear survivin expression in oesophageal squamous cell carcinoma. Br J Cancer 88: 115-119
34. Gray MJ, Van Buren G, Dallas NA et al (2008) Therapeutic targeting of neuropilin-2 on colorectal carcinoma cells implanted in the murine liver. J Natl Cancer Inst 100: 109-120
35. Grieger JC, Samulski RJ (2012) Adeno-associated virus vectorology, manufacturing, and clinical applications. Methods Enzymol 507: 229-254
36. Hajeri PB, Singh SK (2009) siRNAs: their potential as therapeutic agents-part I. Designing of siRNAs. Drug Discov Today 14: 851-858
37. Halder J, Kamat AA, Landen CN Jr et al (2006) Focal adhesion kinase targeting using in vivo short interfering RNA delivery in neutral liposomes for ovarian carcinoma therapy. Clin Cancer Res 12: 4916-4924
38. Han SE, Kang H, Shim GY et al (2008) Novel cationic cholesterol derivative-based liposomes for serum-enhanced delivery of siRNA. Int J Pharm 353: 260-269
39. Huang L, Liu Y (2011) In vivo delivery of RNAi with lipid-based nanoparticles. Annu Rev Biomed Eng 13: 507-530
40. Hughes J, Yadava P, Mesaros R (2010) Liposomal siRNA delivery. Methods Mol Biol 605: 445-459
41. Hwa Kim S, Hyeon Lee S, Tian H et al (2009) Prostate cancer cell-specific VEGF siRNA delivery system using cell targeting peptide conjugated polyplexes. J Drug Target 17: 311-317
42. Jain JP, Ayen WY, Kumar N (2011) Self assembling polymers as polymersomes for drug delivery. Curr Pharm Des 17: 65-79
43. Jeffs LB, Palmer LR, Ambegia EG et al (2005) A scalable, extrusion-free method for efficient liposomal encapsulation of plasmid DNA. Pharm Res 22: 362-372
44. Judge AD, Robbins M, Tavakoli I et al (2009) Confirming the RNAi-mediated mechanism of action of siRNA-based cancer therapeutics in mice. J Clin Invest 119: 661-673
45. Kapoor M, Burgess DJ (2012) Efficient and safe delivery of siRNA using anionic lipids: formulation optimization studies. Int J Pharm 432: 80-90
46. Kim SH, Jeong JH, Lee SH et al (2006a) PEG conjugated VEGF siRNA for anti-angiogenic gene therapy. J Control Release 116: 123-129
47. Kim SH, Mok H, Jeong JH et al (2006b) Comparative evaluation of target-specific GFP gene silencing efficiencies for antisense ODN, synthetic siRNA, and siRNA plasmid complexed with PEI-PEG-FOL conjugate. Bioconjug Chem 17: 241-244
48. Kim SH, Jeong JH, Lee SH et al (2008a) LHRH receptor-mediated delivery of siRNA using polyelectrolyte complex micelles self-assembled from siRNA-PEG-LHRH conjugate and PEI. Bioconjug Chem 19: 2156-2162
49. Kim SH, Jeong JH, Lee SH et al (2008b) Local and systemic delivery of VEGF siRNA using polyelectrolyte complex micelles for effective treatment of cancer. J Control Release 129: 107-116
50. Kwok A, Hart SL (2011) Comparative structural and functional studies of nanoparticle formulations for DNA and siRNA delivery. Nanomedicine 7: 210-219
51. Landen CN, Chavez-Reyes A, Bucana C et al (2005) Therapeutic EphA2 gene targeting in vivo using neutral liposomal small interfering RNA delivery. Cancer Res 65: 6910-6918
52. Landen CN, Chavez-Reyes A, Bucana C et al (2006) Intraperitoneal delivery of liposomal siRNA for therapy of advanced ovarian cancer. Cancer Biol Ther 5: 1708-1713
53. Larsson E, Sander C, Marks D (2010) mRNA turnover rate limits siRNA and microRNA efficacy. Mol Syst Biol 6: 433
54. Lavasanifar A, Xiong XB (2011) Traceable multifunctional micellar nanocarriers for cancertargeted co-delivery of MDR-1 siRNA and doxorubicin. ACS Nano 5: 5202-5213
55. Lee SH, Kim SH, Park TG (2007) Intracellular siRNA delivery system using polyelectrolyte complex micelles prepared from VEGF siRNA-PEG conjugate and cationic fusogenic peptide. Biochem Biophys Res Commun 357: 511-516
56. Lee TB, Park JH, Min YD et al (2008) Epigenetic mechanisms involved in differential MDR1 mRNA expression between gastric and colon cancer cell lines and rationales for clinical chemotherapy. BMC Gastroenterol 8: 33
57. Leonessa F, Clarke R (2003) ATP binding cassette transporters and drug resistance in breast cancer. Endocr Relat Cancer 10: 43-73
58. Lu J, Tan M, Huang WC et al (2009) Mitotic deregulation by survivin in ErbB2-overexpressing breast cancer cells contributes to Taxol resistance. Clin Cancer Res 15: 1326-1334
59. Malek A, Czubayko F, Aigner A (2008) PEG grafting of polyethylenimine (PEI) exerts different effects on DNA transfection and siRNA-induced gene targeting efficacy. J Drug Target 16: 124-139
60. Malek A, Merkel O, Fink L et al (2009) In vivo pharmacokinetics, tissue distribution and underlying mechanisms of various PEI(-PEG)/siRNA complexes. Toxicol Appl Pharmacol 236: 97-108
61. Mao S, Neu M, Germershaus O et al (2006) Influence of polyethylene glycol chain length on the physicochemical and biological properties of poly (ethylene imine)-graft-poly (ethylene glycol) block copolymer/SiRNA polyplexes. Bioconjug Chem 17: 1209-1218
62. Mao S, Sun W, Kissel T (2010) Chitosan-based formulations for delivery of DNA and siRNA. Adv Drug Deliv Rev 62: 12-27
63. Matsumoto S, Christie RJ, Nishiyama N et al (2008) Environment-responsive block copolymer micelles with a disulfide cross-linked core for enhanced siRNA delivery. Biomacromolecules 10: 119-127
64. Matsumura Y, Maeda H (1986) A new concept for macromolecular therapeutics in cancer chemotherapy: mechanism of tumoritropic accumulation of proteins and the antitumor agent smancs. Cancer Res 46: 6387-6392
65. Merkel OM, Beyerle A, Librizzi D et al (2009) Nonviral siRNA delivery to the lung: investigation of PEG-PEI polyplexes and their in vivo performance. Mol Pharm 6: 1246-1260
66. Merritt WM, Lin YG, Spannuth WA et al (2008) Effect of interleukin-8 gene silencing with liposome-encapsulated small interfering RNA on ovarian cancer cell growth. J Natl Cancer Inst 100: 359-372
67. Meyer M, Philipp A, Oskuee R et al (2008) Breathing life into polycations: functionalization with pH-responsive endosomolytic peptides and polyethylene glycol enables siRNA delivery. J Am Chem Soc 130: 3272-3273
68. Morrissey DV, Lockridge JA, Shaw L et al (2005) Potent and persistent in vivo anti-HBV activity of chemically modified siRNAs. Nat Biotechnol 23: 1002-1007
69. Musacchio T, Vaze O, D’Souza G et al (2010) Effective stabilization and delivery of siRNA: reversible siRNA_phospholipid conjugate in nanosized mixed polymeric micelles. Bioconjug Chem 21: 1530-1536
70. Navarro G, Sawant R, Essex S et al (2011a) Phospholipid-polyethylenimine conjugate-based micelle-like nanoparticles for siRNA delivery. Drug Deliv Transl Res 1: 25-33
71. Navarro G, Sawant RR, Biswas S et al (2011b) P-glycoprotein silencing with siRNA delivered by DOPE-modified PEI overcomes doxorubicin resistance in breast cancer cells. Nanomedicine 7: 65-78
72. Ogris M, Brunner S, Schüller S et al (1999) PEGylated DNA/transferrin-PEI complexes: reduced interaction with blood components, extended circulation in blood and potential for systemic gene delivery. Gene Ther 6: 595-605
73. Oishi M, Nagasaki Y, Itaka K et al (2005) Lactosylated poly (ethylene glycol)-siRNA conjugate through acid-labile β-thiopropionate linkage to construct pH-sensitive polyion complex micelles achieving enhanced gene silencing in hepatoma cells. J Am Chem Soc 127: 1624-1625
74. Ozpolat B, Akar U, Tekedereli I et al (2008) Targeted silencing of Bcl-2 by liposomal siRNAnanovectors leads to autophagic and apoptotic cell death in in vivo breast cancer models. Proc Annu Meet Am Assoc Cancer Res 2008: 4928
75. Ozpolat B, Sood A, Lopez-Berestein G (2010) Nanomedicine based approaches for the delivery of siRNA in cancer. J Intern Med 267: 44-53
76. Pai SI, Lin YY, Macaes B et al (2006) Prospects of RNA interference therapy for cancer. Gene Ther 13: 464-477
77. Pal A, Ahmad A, Khan S et al (2005) Systemic delivery of RafsiRNA using cationic cardiolipin liposomes silences Raf-1 expression and inhibits tumor growth in xenograft model of human prostate cancer. Int J Oncol 26: 1087-1091
78. Passirani C, Benoit J (2005) Complement activation by injectable colloidal drug carriers. Biomaterials for delivery and targeting of proteins and nucleic acids. CRC, New York, NY, pp 187-230
79. Pecot CV, Calin GA, Coleman RL et al (2011) RNA interference in the clinic: challenges and future directions. Nat Rev Cancer 11: 59-67
80. Pirollo KF, Chang EH (2008) Targeted delivery of small interfering RNA: approaching effective cancer therapies. Cancer Res 68: 1247-1250
81. Saito G, Swanson JA, Lee KD (2003) Drug delivery strategy utilizing conjugation via reversible disulfide linkages: role and site of cellular reducing activities. Adv Drug Deliv Rev 55: 199-215
82. Santel A, Aleku M, Keil O et al (2006) A novel siRNA-lipoplex technology for RNA interference in the mouse vascular endothelium. Gene Ther 13: 1222-1234
83. Santel A, Aleku M, Roder N et al (2010) Atu027 prevents pulmonary metastasis in experimental and spontaneous mouse metastasis models. Clin Cancer Res 16: 5469-5480
84. Sato A, Choi SW, Hirai M et al (2007a) Polymer brush-stabilized polyplex for a siRNA carrier with long circulatory half-life. J Control Release 122: 209-216
85. Sato A, Takagi M, Shimamoto A et al (2007b) Small interfering RNA delivery to the liver by intravenous administration of galactosylated cationic liposomes in mice. Biomaterials 28: 1434-1442
86. Sawant R, Torchilin V (2010a) Intracellular transduction using cell-penetrating peptides. Mol Biosyst 6: 628-640
87. Sawant RR, Torchilin VP (2010b) Polymeric micelles: polyethylene glycol-phosphatidylethanolamine (PEG-PE)-based micelles as an example. Methods Mol Biol 624: 131-149
88. Scholz C, Wagner E (2012) Therapeutic plasmid DNA versus siRNA delivery: common and different tasks for synthetic carriers. J Control Release 161: 554-565
89. Shinohara ET, Gonzalez A, Massion PP et al (2005) Nuclear survivin predicts recurrence and poor survival in patients with resected nonsmall cell lung carcinoma. Cancer 103: 1685-1692
90. Singh S, Narang AS, Mahato RI (2011) Subcellular fate and off-target effects of siRNA, shRNA, and miRNA. Pharm Res 28: 2996-3015
91. Soutschek J, Akinc A, Bramlage B et al (2004) Therapeutic silencing of an endogenous gene by systemic administration of modified siRNAs. Nature 432: 173-178
92. Spagnou S, Miller AD, Keller M (2004) Lipidic carriers of siRNA: differences in the formulation, cellular uptake, and delivery with plasmid DNA. Biochemistry 43: 13348-13356
93. Sun T-M, Du J-Z, Yan L-F et al (2008) Self-assembled biodegradable micellar nanoparticles of amphiphilic and cationic block copolymer for siRNA delivery. Biomaterials 29: 4348-4355
94. Sun T-M, Du J-Z, Yao Y-D et al (2011) Simultaneous delivery of siRNA and paclitaxel via a "twoin-one” micelleplex promotes synergistic tumor suppression. ACS Nano 5: 1483-1494
95. Sutton D, Kim S, Shuai X et al (2006) Efficient suppression of secretory clusterin levels by polymer-siRNA nanocomplexes enhances ionizing radiation lethality in human MCF-7 breast cancer cells in vitro. Int J Nanomedicine 1: 155-162
96. Takemoto H, Ishii A, Miyata K et al (2010) Polyion complex stability and gene silencing efficiency with a siRNA-grafted polymer delivery system. Biomaterials 31: 8097-8105
97. Tian L, Bae YH (2012) Cancer nanomedicines targeting tumor extracellular pH. Colloids Surf B Biointerfaces 99: 116-126
98. Tolcher AW, Quinn DI, Ferrari A et al (2012) A phase II study of YM155, a novel small-molecule suppressor of survivin, in castration-resistant taxane-pretreated prostate cancer. Ann Oncol 23: 968-973
99. Torchilin VP (2006) Multifunctional nanocarriers. Adv Drug Deliv Rev 58: 1532-1555
100. Torchilin V (2008) Antibody-modified liposomes for cancer chemotherapy. Expert Opin Drug Deliv 5: 1003-1025
101. Wu Y, Wang W, Chen Y et al (2010) The investigation of polymer-siRNA nanoparticle for gene therapy of gastric cancer in vitro. Int J Nanomedicine 5: 129-136
102. Xiong XB, Uludag H, Lavasanifar A (2009) Biodegradable amphiphilic poly (ethylene oxide)-block-polyesters with grafted polyamines as supramolecular nanocarriers for efficient siRNA delivery. Biomaterials 30: 242-253
103. Xiong XB, Uludağ H, Lavasanifar A (2010) Virus-mimetic polymeric micelles for targeted siRNA delivery. Biomaterials 31: 5886-5893
104. Yano J, Hirabayashi K, Nakagawa S et al (2004) Antitumor activity of small interfering RNA/cationic liposome complex in mouse models of cancer. Clin Cancer Res 10: 7721-7726
105. Zelphati O, Uyechi LS, Barron LG et al (1998) Effect of serum components on the physicochemical properties of cationic lipid/oligonucleotide complexes and on their interactions with cells. Biochim Biophys Acta 1390: 119-133
106. Zhao H, Yung LY (2008) Selectivity of folate conjugated polymer micelles against different tumor cells. Int J Pharm 349: 256-268
107. Zhu C, Jung S, Luo S et al (2010) Co-delivery of siRNA and paclitaxel into cancer cells by biodegradable cationic micelles based on PDMAEMA-PCL-PDMAEMA triblock copolymers. Biomaterials 31: 2408-2416